CHICAGO–(BUSINESS WIRE)–Intelligent Medical Objects (IMO), a healthcare data enablement Company, announced today three new products for general availability: IMO Precision Normalize with Natural Language Processing (NLP), IMO Precision Sets, and IMO Discovery for Problems. These offerings represent a new era for the company, which has a 30-year history of solving clinical terminology issues for providers and electronic health records (EHRs). More recently, IMO has been expanding its product portfolio to leverage its foundation in clinical terminology and coding to benefit other areas of the healthcare ecosystem.
“IMO is problem solving for other parts of healthcare the same way we did in the early days of EHRs, by leveraging our foundation in terminology to standardize and normalize data,” said Ann Barnes, IMO’s CEO. “Our customers are looking for health IT solutions that streamline processes and accelerate innovation and IMO is moving quickly to meet these needs.”
In a survey commissioned by IMO earlier this year, providers cited improving clinical care and better data quality standards as top priorities for their organizations. IMO’s new solutions are designed to help organizations across the healthcare ecosystem extract more value from clinical data, including the ability to:
The new products aim to tackle well-known industry pain points, including:
About Intelligent Medical Objects
Intelligent Medical Objects is a healthcare data enablement company that ensures clinical data integrity and quality — making patient information fit-for-purpose across the healthcare ecosystem, from hospitals to health IT, pharma, public health, payers, and beyond.
IMO’s vast footprint in EHRs powers our ability to capture and preserve clinical intent at the highest level of specificity. Our secure technology platform and products then help our clients to transform and extract the greatest value from their data. In short, IMO is the catalyst that enables accurate documentation, precise population cohorting, optimized reimbursements, robust analytics, and better care decisions to optimize patient outcomes.
Contacts
Jessica Emond
202.257.1808
jemond@imohealth.com
Rachel Hutman
301.801.5540
Rachel@fordhutmanmedia.com
NEW YORK, July 4, 2024 /PRNewswire/ -- The global breast tissue expander market size is estimated to…
CHICAGO, July 4, 2024 /PRNewswire/ -- The global microscopy market is poised for significant growth, expected…
Toronto, Ontario--(Newsfile Corp. - July 4, 2024) - FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE)…
MARBURG, Germany, July 04, 2024 (GLOBE NEWSWIRE) -- Global biotechnology leader CSL Behring (ASX: CSL)…
SKYSCRAPER-06 evaluating tiragolumab plus Tecentriq and chemotherapy did not meet the primary endpoints of progression-free…
ICPO Center NuMeRI ICPO Foundation signed the contract with Nuclear Medicine Research Infrastructure (NuMeRI) to…